Last reviewed · How we verify
URIDINE TRIACETATE
At a glance
| Generic name | URIDINE TRIACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
Common side effects
- Vomiting
- Nausea
- Diarrhea
Serious adverse events
- Grade 3 Nausea and Vomiting
Key clinical trials
- Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria (PHASE3)
- Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer (PHASE3)
- S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach (PHASE2)
- RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease (PHASE1)
- Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- URIDINE TRIACETATE CI brief — competitive landscape report
- URIDINE TRIACETATE updates RSS · CI watch RSS